Is alglucosidase alfa FDA and EMA approved?

Yes. It was approved by the US FDA and the European Medicines Agency in 2006; in the US, Lumizyme is used for late-onset disease. It is a prescription biologic, not an over-the-counter product.

It replaces the deficient lysosomal enzyme acid alpha-glucosidase, entering cells via mannose-6-phosphate receptors to clear glycogen that accumulates in muscle.

What are the main risks?

Infusion-associated and hypersensitivity reactions are common, and most patients form anti-drug antibodies; high titres can reduce effectiveness, particularly in CRIM-negative infants. Severe cardiorespiratory reactions can occur in susceptible infants.

Does it cure Pompe disease?

No. It is not a cure; it is a lifelong treatment shown to prolong survival and improve or stabilize motor and respiratory outcomes, with response varying by disease type, age, and antibody status.

EMA-approvedaka Myozyme, Lumizyme

Alglucosidase alfa — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Alglucosidase alfa (also known as Myozyme) is a peptide catalogued under Enzymes (Pompe disease enzyme replacement). Neutral reference entry; EU status: EU-approved prescription medicine.

What is Alglucosidase alfa?

Alglucosidase alfa (brand names Myozyme and Lumizyme) is a recombinant human acid alpha-glucosidase (rhGAA) approved as enzyme replacement therapy for Pompe disease (acid maltase deficiency, glycogen storage disease type II). It received US FDA approval in 2006 and EU (EMA) approval as Myozyme in 2006, with Lumizyme later approved in the US for late-onset disease.

It is the first and long-standing disease-specific treatment for Pompe disease and is supported by a high level of evidence, including two pivotal prospective clinical trials in infantile-onset and late-onset patients.

It is a prescription-only biologic given by trained clinicians, not a research chemical or supplement.

How does Alglucosidase alfa work?

Alglucosidase alfa is a recombinant form of the lysosomal enzyme acid alpha-glucosidase, which is deficient in Pompe disease.

Delivered intravenously, it is taken up by cells via mannose-6-phosphate receptors and traffics to lysosomes, where it hydrolyses accumulated lysosomal glycogen and reduces glycogen storage in cardiac and skeletal muscle.

What does the research say about Alglucosidase alfa?

In infantile-onset Pompe disease, alglucosidase alfa markedly prolonged ventilator-free and overall survival and reduced cardiomyopathy compared with the untreated natural history. ^[1]
In late-onset Pompe disease, a randomized placebo-controlled trial showed improved walking distance (6-minute walk) and stabilization of pulmonary function over 78 weeks. ^[2]
Inducing immune tolerance in CRIM-negative patients can enhance the clinical response to enzyme replacement therapy by limiting neutralizing antibody formation. ^[3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease — Kishnani PS et al., Neurology 2007. (Prospective clinical trial (infantile-onset))
[2] A randomized study of alglucosidase alfa in late-onset Pompe's disease — van der Ploeg AT et al., The New England Journal of Medicine 2010. (Randomized, double-blind, placebo-controlled trial (LOTS))
[3] Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance — Sun B et al., American Journal of Human Genetics 2007. (Preclinical/translational study)
[4] Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience — Bali DS et al., American Journal of Medical Genetics Part C 2012. (Laboratory/clinical review)
[5] Glycogen storage disease types I and II: treatment updates — Koeberl DD et al., Journal of Inherited Metabolic Disease 2007. (Review)
[6] Pompe Disease — Adam MP et al., GeneReviews (University of Washington, Seattle) 1993. (Peer-reviewed clinical review (updated periodically))

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

For context only and not as medical advice, alglucosidase alfa is given as an intravenous infusion, commonly at a dose around 20 mg/kg every two weeks, with the rate titrated upward gradually.

Actual dosing, premedication, and monitoring are individualized by a specialist metabolic team.

Side effects & safety profile

Infusion-associated reactions (including urticaria, flushing, fever, and, rarely, anaphylaxis/hypersensitivity) are common and warrant slow infusion, monitoring, and premedication where needed.

Most patients develop anti-drug (IgG) antibodies; high sustained titres, especially in CRIM-negative infantile-onset patients, are associated with reduced efficacy, which is why immune tolerance induction is used.

It carries warnings regarding acute cardiorespiratory failure risk in susceptible infants and must be administered under clinical supervision.

Stacking & combinations

In CRIM-negative or antibody-high patients it is combined with immunomodulatory (immune tolerance induction) regimens rather than with other supplements, and any concomitant therapy is directed by the treating specialist.

Finding Alglucosidase alfa vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is an approved enzyme replacement therapy for Pompe disease (acid alpha-glucosidase deficiency), marketed as Myozyme and Lumizyme, and given by intravenous infusion under specialist care.

References

[1] Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease — Kishnani PS et al., Neurology 2007. PMID: 17151339. View sourceStudy: Prospective clinical trial (infantile-onset)Alglucosidase alfa reduced the risk of death and of invasive ventilation and improved cardiomyopathy in infantile-onset Pompe disease.
[2] A randomized study of alglucosidase alfa in late-onset Pompe's disease — van der Ploeg AT et al., The New England Journal of Medicine 2010. PMID: 20393176. View sourceStudy: Randomized, double-blind, placebo-controlled trial (LOTS)Over 78 weeks, treated late-onset patients had improved 6-minute walk distance and stabilized pulmonary function versus placebo.
[3] Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance — Sun B et al., American Journal of Human Genetics 2007. PMID: 17924344. View sourceStudy: Preclinical/translational studyImmune tolerance induction reduced neutralizing antibodies and enhanced the efficacy of enzyme replacement therapy.
[4] Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience — Bali DS et al., American Journal of Medical Genetics Part C 2012. PMID: 22252923. View sourceStudy: Laboratory/clinical reviewCRIM status, predictable from GAA genotype, is a key determinant of antibody response and treatment outcome.
[5] Glycogen storage disease types I and II: treatment updates — Koeberl DD et al., Journal of Inherited Metabolic Disease 2007. PMID: 17308886. View sourceStudy: ReviewReviews enzyme replacement therapy for Pompe disease and its clinical impact and limitations.
[6] Pompe Disease — Adam MP et al., GeneReviews (University of Washington, Seattle) 1993. PMID: 20301438. View sourceStudy: Peer-reviewed clinical review (updated periodically)Provides an authoritative overview of Pompe disease diagnosis, natural history, and enzyme replacement therapy management.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.